Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Non-cash Items (2019 - 2024)

Harvard Bioscience (HBIO) has disclosed Non-cash Items for 6 consecutive years, with $91000.0 as the latest value for Q2 2024.

  • On a quarterly basis, Non-cash Items changed N/A to $91000.0 in Q2 2024 year-over-year; TTM through Jun 2024 was $91000.0, a N/A change, with the full-year FY2023 number at $1.8 million, up 866.32% from a year prior.
  • Non-cash Items was $91000.0 for Q2 2024 at Harvard Bioscience, down from $964000.0 in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $5.6 million in Q4 2021 to a low of $91000.0 in Q2 2024.
  • A 5-year average of $1.9 million and a median of $1.4 million in 2023 define the central range for Non-cash Items.
  • Peak YoY movement for Non-cash Items: soared 870.04% in 2020, then tumbled 96.58% in 2022.
  • Harvard Bioscience's Non-cash Items stood at $2.5 million in 2020, then surged by 122.74% to $5.6 million in 2021, then crashed by 96.58% to $190000.0 in 2022, then surged by 866.32% to $1.8 million in 2023, then crashed by 95.04% to $91000.0 in 2024.
  • Per Business Quant, the three most recent readings for HBIO's Non-cash Items are $91000.0 (Q2 2024), $964000.0 (Q1 2024), and $1.8 million (Q4 2023).